Immunome (NASDAQ:IMNM) Shares Gap Up to $13.82

Shares of Immunome, Inc. (NASDAQ:IMNM) gapped up before the market opened on Tuesday . The stock had previously closed at $13.82, but opened at $14.26. Immunome shares last traded at $14.01, with a volume of 162,041 shares traded.

Wall Street Analyst Weigh In

IMNM has been the subject of a number of analyst reports. JPMorgan Chase & Co. initiated coverage on shares of Immunome in a research report on Tuesday. They issued an “overweight” rating and a $24.00 target price for the company. Leerink Partnrs reaffirmed an “outperform” rating on shares of Immunome in a research report on Monday, January 29th. SVB Leerink initiated coverage on shares of Immunome in a research report on Monday, January 29th. They issued an “outperform” rating and a $30.00 target price for the company. Wedbush raised their target price on shares of Immunome from $27.00 to $33.00 and gave the company an “outperform” rating in a research report on Monday, April 1st. Finally, Guggenheim initiated coverage on shares of Immunome in a research report on Monday, April 15th. They issued a “buy” rating and a $35.00 target price for the company. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Immunome currently has an average rating of “Buy” and an average price target of $30.50.

Immunome Price Performance

The business’s 50 day simple moving average is $21.58 and its 200 day simple moving average is $15.28.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings results on Thursday, March 28th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.26). The firm had revenue of $3.83 million during the quarter, compared to analyst estimates of $3.40 million. Immunome had a negative net margin of 761.92% and a negative return on equity of 69.74%. Equities research analysts expect that Immunome, Inc. will post -1.91 EPS for the current year.

Institutional Trading of Immunome

Large investors have recently added to or reduced their stakes in the company. Dorsey Wright & Associates acquired a new stake in Immunome in the third quarter valued at $26,000. Jump Financial LLC acquired a new stake in shares of Immunome during the 4th quarter worth about $172,000. Acadian Asset Management LLC acquired a new stake in shares of Immunome during the 3rd quarter worth about $414,000. Clear Creek Financial Management LLC acquired a new stake in shares of Immunome during the 1st quarter worth about $547,000. Finally, Emfo LLC acquired a new stake in shares of Immunome during the 4th quarter worth about $633,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.